

CLEVELAND BIOLABS INC  
Form 8-K  
December 18, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): December 17, 2013**

**Cleveland BioLabs, Inc.**

(Exact Name of Issuer as Specified in Charter)

**DELAWARE**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**001-32954**  
(Commission File Number)

**20-0077155**  
(I.R.S. Employer Identification  
Number)

**73 High Street**  
**Buffalo, NY**  
(Address of Principal Executive Offices)

**(716) 849-6810**  
(Registrant's Telephone Number, Including Area Code)

**14203**  
(Zip Code)

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Edgar Filing: CLEVELAND BIOLABS INC - Form 8-K

On December 18, 2013, Cleveland BioLabs, Inc. (the "Company") issued a press release announcing that Jean Viallet, M.D., Chief Development Officer, has resigned from the Company to pursue other opportunities. Dr. Viallet will remain with the Company through January 3, 2014. A copy of the Company's press release is filed herewith as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(d)

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
99.1	Press Release dated December 18, 2013.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Cleveland BioLabs, Inc.**

Date: December 18, 2013

By: /s/ YAKOV KOGAN

Name: Yakov Kogan, Ph.D., M.B.A.

Title: Chief Executive Officer